What’s the problem?
The new Yaz gallbladder disease lawsuit accuses Bayer of negligence, product liability, breach of implied and express warranties, fraudulent concealment, and negligent misrepresentation. The plaintiff is seeking compensatory damages for her Yaz injuries.
The complaint is among the latest to join the coordinated Yaz proceedings in California state court. Yaz lawsuits filed on the federal level have been consolidated into a multidistrict litigation (MDL) before Chief Judge David R. Herndon in the Southern District of Illinois. New Jersey has also formed a state level Yaz multicounty litigation (formerly called a mass tort).
First approved by the U.S. Food & Drug Administration (FDA) in 2008, Yaz was designed to be a successor to Yasmin, which was released in 2001. Both drugs contain the active ingredient drospirenone, which has recently been linked to serious side effects including:
- Blood Clots
- Deep Vein Thrombosis (DVT)
- Venous Thromboembolism (VTE)
- Pulmonary Embolism (PE)
- Cerebrovascular Accidents (CVA)
- Heart Attack
- Myocardial Infarction
- Gallbladder Disease / Injury (cholecystitis)
- Gallbladder Removal (cholecystectomy)
Additionally, a recent study conducted by researchers at the University of British Columbia found that women who take Yaz have a significantly increased risk of developing irritable bowel syndrome (IBS).
To date, Bayer has paid out nearly $403 million to more than 1,800 plaintiffs in Yaz litigation. And though these numbers may appear astronomical at first glance, the company still faces an estimated 10,000 Yaz lawsuits pending in courthouses around the country. Bayer has stated that it has set aside an additional $610.5 million to resolve the cases, which would bring the ground total to over $1 billion. However, industry insiders have estimated that Bayer may end up paying out as much as $2.5 billion in Yaz settlements once the litigation is complete.